Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
US6294537A · kind A · utility
5Cited by
2References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 7, 1999 |
| Grant date | Sep 25, 2001 |
| Priority date | — |
| Expiry date | May 7, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/50
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating diseases which involve interaction of neurokinin B with NK.sub.3 receptors in humans. The method comprises administering a therapeutically effective amount of a NK.sub.3 antagonist compound having the formula: ##STR1## in which: R.sub.1 and R.sub.11 together represent a --(CH.sub.2).sub.3 -group.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.